VC fund profile · evidence-aware directory data
ORIX USA Growth Capital stages, portfolio and investment profile
ORIX USA's Growth Capital business provides financing to technology and healthcare companies. Its own strategy page describes debt structures and equity co-investments, including senior and junior lending. On October 21, 2026, the business confirmed participation in Kevel's $52M financing alongside Fulcrum Equity Partners, dunnhumby Ventures and Iberis Capital. Managing director Blake Zhang's statement emphasizes increasing complexity across onsite, offsite and in-store retail media. The deal announcement does not disclose ORIX's allocation or the financing's equity/debt split. This profile represents the ORIX USA business, not a separately announced fund vehicle.
Keep track of ORIX USA Growth Capital
Save this profile to your VCT watchlist for a quick return.
Stage-based planning range
$100K–$1M
This is a planning range inferred from stage coverage, not a firm-disclosed check size.
Methodology: Stage bucket inferred from the rounds a fund leads or invests in.
No firm-specific check-size disclosure is recorded.
Investment stages
Leads: Not recorded
Participates: Growth
Sector focus
Not recorded
Geography
Not recorded
Founded Not recorded
Fund size / AUM
Not recorded
A separate fund-size evidence record is not yet available.
Portfolio in our directory
1
Linked startup profiles
Latest fund vehicle
Not recorded
Vehicle name, size, and vintage are not yet structured.
Recent tracked investment
Not recorded
No dated round explicitly links this fund.
Rounds they lead
Rounds they invest
Last verified: 2026-10-24. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.
Portfolio companies we track
Startups in our directory that list ORIX USA Growth Capital as an investor (1 total).
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.